IP Library › Granted Patent US 8,071,762
Granted Patent B2
US 8,071,762 · App. 12/112,105 · Granted Dec 6, 2011

Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Assignee: Abbott Laboratories
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,071,762
App. No.
12/112,105
Granted
Dec 6, 2011
Kind
B2
Abstract

The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X 1 -X 5 , R 5 -R 8b , Z 1 -Z 2 and Ar 1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.

Claims (78)

1. A compound selected from the group consisting of

N-(5-chloro-2,3-dihydro-1H-inden-1-yl)-N′-1H-indazol-4-ylurea;

N-(5-fluoro-2,3-dihydro-1H-inden-1-yl)-N′-1H-indazol-4-ylurea;

N-(4,5-dimethoxy-2,3-dihydro-1H-inden-1-yl)-N′-1H-indazol-4-ylurea;

N-1H-indazol-4-yl-N′-(5-methoxy-2,3-dihydro-1H-inden-1-yl)urea;

N-(5,6-dimethoxy-2,3-dihydro-1H-inden-1-yl)-N′-1H-indazol-4-ylurea;

N-1H-indazol-4-yl-N′-(6-methoxy-2,3-dihydro-1H-inden-1-yl)urea;

N-[(1S)-4,5-dimethoxy-2,3-dihydro-1H-inden-1-yl]-N′-1H-indazol-4-ylurea;

N-[(1R)-4,5-dimethoxy-2,3-dihydro-1H-inden-1-yl]-N′-1H-indazol-4-ylurea;

N-1H-indazol-4-yl-N′-[(1S)-5-methoxy-2,3-dihydro-1H-inden-1-yl]urea;

N-1H-indazol-4-yl-N′-[(1R)-5-methoxy-2,3-dihydro-1H-inden-1-yl]urea;

N-1H-indazol-4-yl-N′-[5-(2-methoxy-1,1-dimethylethyl)-2,3-dihydro-1H-inden-1-yl]urea;

N-[5-(2-hydroxy-1,1-dimethylethyl)-2,3-dihydro-1H-inden-1-yl]-N′-1H-indazol-4-ylurea;

N-(5-tert-butyl-2-fluoro-2,3-dihydro-1H-inden-1-yl)-N′-1H-indazol-4-ylurea;

N-[(1R,2S)-5-tert-butyl-2-fluoro-2,3-dihydro-1H-inden-1-yl]-N′-1H-indazol-4-ylurea;

N-[(1S,2S)-5-tert-butyl-2-fluoro-2,3-dihydro-1H-inden-1-yl]-N′-1H-indazol-4-ylurea;

N-[(1S,2R)-5-tert-butyl-2-fluoro-2,3-dihydro-1H-inden-1-yl]-N′-1H-indazol-4-ylurea;

N-1H-indazol-4-yl-N′-(6-fluoro-2,3-dihydro-1H-inden-1-yl)urea;

N-1H-indazol-4-yl-N′-(6-methyl-2,3-dihydro-1H-inden-1-yl)urea;

N-(5-tert-butyl-2,2-difluoro-2,3-dihydro-1H-inden-1-yl)-N′-1H-indazol-4-ylurea;

1-(5-tert-butyl-indan-2-yl)-3-(1H-indazol-4-yl)-urea;

N-1H-indazol-4-yl-N′-(7-methyl-2,3-dihydro-1H-inden-1-yl)urea;

N-1H-indazol-4-yl-N′-(5-methyl-2,3-dihydro-1H-inden-1-yl)urea;

N-1H-indazol-4-yl-N′-(5-isopropyl-2,3-dihydro-1H-inden-1-yl)urea;

1-[5-(Cyano-isopropyl)-indan-1-yl]-3-(1H-indazol-4-yl)-urea;

N-[(1R)-5-(1-cyano-1-methylethyl)-2,3-dihydro-1H-inden-1-yl]-N′-1H-indazol-4-ylurea;

N-[(1S)-5-(1-cyano-1-methylethyl)-2,3-dihydro-1H-inden-1-yl]-N′-1H-indazol-4-ylurea;

N-1H-indazol-4-yl-N′-[4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]urea;

N-(4-chloro-2,3-dihydro-1H-inden-1-yl)-N′-1H-indazol-4-ylurea;

N-1H-indazol-4-yl-N′-[4-(trifluoromethoxy)-2,3-dihydro-1H-inden-1-yl]urea;

N-(4-bromo-2,3-dihydro-1H-inden-1-yl)-N′-1H-indazol-4-ylurea;

N-[4-(cyanomethyl)-2,3-dihydro-1H-inden-1-yl]-N′-1H-indazol-4-ylurea; and

N-1H-indazol-4-yl-N′-(4-methyl-2,3-dihydro-1H-inden-1-yl)urea;

or a pharmaceutically acceptable salt thereof.

2. A compound that is amorphous N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-1H-indazol-4-ylurea, or a pharmaceutically acceptable salt thereof.

3. A compound selected from the group consisting of

N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-1H-indazol-4-ylurea, hydrochloride;

N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-1H-indazol-4-ylurea, tosylate; and

N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-1H-indazol-4-ylurea, benzenesulfonate.

4. A compound selected from the group consisting of

N-(1-acetyl-1H-indazol-4-yl)-N′-(5,6-dimethoxy-2,3-dihydro-1H-inden-1-yl)urea; and

N-(1-acetyl-1H-indazol-4-yl)-N′-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]urea;

or a pharmaceutically acceptable salt thereof.

5. A compound selected from the group consisting of

N-(6-fluoro-5-piperidin-1-yl-2,3-dihydro-1H-inden-1-yl)-N′-1H-indazol-4-ylurea;

N-1H-indazol-4-yl-N′-(4-piperidin-1-yl-2,3-dihydro-1H-inden-1-yl)urea;

N-1H-indazol-4-yl-N′-{5-[4-(trifluoromethyl)piperidin-1-yl]-2,3-dihydro-1H-inden-1-yl}urea;

N-1H-indazol-4-yl-N′-(5-cis-octahydroisoquinolin-2(1H)-yl-2,3-dihydro-1H-inden-1-yl)urea;

N-[5-(1,4′-bipiperidin-1′-yl)-2,3-dihydro-1H-inden-1-yl]-N′-1H-indazol-4-ylurea;

N-1H-indazol-4-yl-N′-[5-(4-phenylpiperidin-1-yl)-2,3-dihydro-1H-inden-1-yl]urea;

N-1H-indazol-4-yl-N′-[5-(4-phenylpiperazin-1-yl)-2,3-dihydro-1H-inden-1-yl]urea;

N-1H-indazol-4-yl-N′-[5-(4-methylpiperidin-1-yl)-2,3-dihydro-1H-inden-1-yl]urea;

N-1H-indazol-4-yl-N′-[5-(3-methylpiperidin-1-yl)-2,3-dihydro-1H-inden-1-yl]urea;

N-1H-indazol-4-yl-N′-[5-(2-oxopiperidin-1-yl)-2,3-dihydro-1H-inden-1-yl]urea;

N-1H-indazol-4-yl-N′-[5-(2-methylpiperidin-1-yl)-2,3-dihydro-1H-inden-1-yl]urea;

N-(4-azepan-1-yl-2,3-dihydro-1H-inden-1-yl)-N′-1H-indazol-4-ylurea;

N-1H-indazol-4-yl-N′-[4-(4-methylpiperidin-1-yl)-2,3-dihydro-1H-inden-1-yl]urea;

N-1H-indazol-4-yl-N′-[4-(3-methylpiperidin-1-yl)-2,3-dihydro-1H-inden-1-yl]urea;

N-1H-indazol-4-yl-N′-[4-(2-methylpiperidin-1-yl)-2,3-dihydro-1H-inden-1-yl]urea;

N-1H-indazol-4-yl-N′-[(1R)-4-piperidin-1-yl-2,3-dihydro-1H-inden-1-yl]urea;

N-1H-indazol-4-yl-N′-[(1S)-4-piperidin-1-yl-2,3-dihydro-1H-inden-1-yl]urea;

N-1H-indazol-4-yl-N′-(4-pyrrolidin-1-yl-2,3-dihydro-1H-inden-1-yl)urea;

N-1H-indazol-4-yl-N′-[4-(2-methylpyrrolidin-1-yl)-2,3-dihydro-1H-inden-1-yl]urea;

N-[4-(2-azabicyclo[2.2.1]hept-2-yl)-2,3-dihydro-1H-inden-1-yl]-N′-1H-indazol-4-ylurea;

N-1H-indazol-4-yl-N′-(4-octahydroisoquinolin-2(1H)-yl-2,3-dihydro-1H-inden-1-yl)urea;

1-[5-(1,1-Dioxo-1-thiomorpholin-4-yl)-indan-1-yl]-3-(1H-indazol-4-yl)-urea;

1-(1H-Indazol-4-yl)-3-(4-morpholin-4-yl-indan-1-yl)-urea;

1-(1H-Indazol-4-yl)-3-(4-[1,4]oxazepan-4-yl-indan-1-yl)-urea;

1-[4-(2,6-Dimethyl-morpholin-4-yl)-indan-1-yl]-3-(1H-indazol-4-yl)-urea;

1-(1H-Indazol-4-yl)-3-[4-(4-methyl-piperazin-1-yl)-indan-1-yl]-urea;

1-(1H-Indazol-4-yl)-3-(4-pyridin-3-yl-indan-1-yl)-urea;

1-(1H-Indazol-4-yl)-3-(4-pyridin-4-yl-indan-1-yl)-urea;

1-(1H-Indazol-4-yl)-3-(4-pyridin-2-yl-indan-1-yl)-urea;

1-[4-(4-Fluoro-piperidin-1-yl)-indan-1-yl]-3-(1H-indazol-4-yl)-urea;

1-[4-(3-Fluoro-piperidin-1-yl)-indan-1-yl]-3-(1H-indazol-4-yl)-urea;

1-[4-(3,3-Difluoro-piperidin-1-yl)-indan-1-yl]-3-(1H-indazol-4-yl)-urea; and

1-[4-(4,4-Difluoro-piperidin-1-yl)-indan-1-yl]-3-(1H-indazol-4-yl)-urea;

or a pharmaceutically acceptable salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030176/0968 →
Continuity (4)
Division 10864068 · Jun 9, 2004
Continuation In Part 11258980 · Oct 26, 2005
Provisional Application 60477894 · Jun 12, 2003
Related Publication 20080287676A1 · Nov 20, 2008